Lifeboat Foundation

A team of researchers at Umeå University has discovered that an enzyme in human cells has probably evolved from an ancient single-celled organism. The enzyme’s unique properties mean that it could be used as a building block in the design of new enzymes, for example in processing wood raw materials. The discoveries are presented in Science Advances.

Life on Earth is divided into three groups of organisms: bacteria, archaea and eukaryotes, with humans belonging to the last group, the eukaryotes. One theory is that we evolved from archaea, which in turn may have evolved from bacteria.

Now, a team of researchers from the Department of Chemistry at Umeå University has discovered clear traces of an archaea (odinarchaeota) in an enzyme found in the nucleus of human cells. The human enzyme is called AK6 and has a variety of functions, such as energy metabolism, genome stabilization and programmed cell death.

In a study recently published in the journal Nature Biomedical Engineering, researchers from Kanazawa University use a method called “lasso-grafting” to design therapeutics with enhanced longevity and brain penetration.

Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors. Unfortunately, delivering adequate concentrations of these molecules to the brain for treating neurological conditions like Alzheimer’s disease is challenging as they are either cleared out of the blood very quickly or do not penetrate neural tissue effectively.

A research team led by Kunio Matsumoto and Katsuya Sakai at Kanazawa University in collaboration with Junichi Takagi, Osaka University and Hiroaki Suga, the University of Tokyo has now used a technique called “lasso-grafting” to design molecules that replicate growth factors with longer retention in the body and brain penetration.

This time I come to talk about a new concept in this Age of Artificial Intelligence and the already insipid world of Social Networks. Initially, quite a few years ago, I named it “Counterpart” (long before the TV series “Counterpart” and “Black Mirror”, or even the movie “Transcendence”).

It was the essence of the ETER9 Project that was taking shape in my head.

Over the years and also with the evolution of technologies — and of the human being himself —, the concept “Counterpart” has been getting better and, with each passing day, it makes more sense!

Imagine a purely digital receptacle with the basics inside, like that Intermediate Software (BIOS⁽¹⁾) that computers have between the Hardware and the Operating System. That receptacle waits for you. One way or another, it waits patiently for you, as if waiting for a Soul to come alive in the ether of digital existence.

Continue reading “Digital Doubles and Second Selves” »

In laboratory mice, pituitary dwarfism caused by genetic reduction or elimination of the activity of growth hormone (GH) significantly extends lifespan. The effects of congenital pituitary dwarfism on human longevity are not well documented. To analyse the effects of untreated pituitary dwarfism on human lifespan, the longevity of a diverse group of widely known little people, the 124 adults who played “Munchkins” in the 1939 movie The Wizard of Oz was investigated. Survival of “Munchkin” actors with those of controls defined as cast members of The Wizard of Oz and those of other contemporary Academy Award winning Hollywood movies was compared. According to the Kaplan–Meier survival curves, survival of female and male “Munchkin” actors was shorter than cast controls and Hollywood controls of respective sexes.

Michael Rae (Science Writer for SENS Research Foundation) asks Dr. Amit Sharma questions about his ApoptoSENS area of research.

This video is part of our End of Year Campaign 2022.

Continue reading “Ask Me Anything about ApoptoSENS — with Dr. Amit Sharma and Michael Rae” »

Past neuroscience studies have consistently demonstrated that the aging of the mammalian nervous system is liked with a decline in the volume and functioning of white matter, nerve fibers found in deep brain tissues. Although this is now a well-established finding, the mechanisms underpinning the decline of white matter and associated pathologies are poorly understood.

Researchers at Ludwig Maximilian University (LMU) of Munich, Technical University of Munich, the German Center for Neurodegenerative Diseases, Munich Cluster of Systems Neurology and University Hospital Würzburg have recently carried out a study aimed at better understanding the neural mechanisms that might result in the deterioration of white matter. Their findings, published in Nature Neuroscience, suggest that adaptive immune responses could promote the loss of cells in aging white matter.

“Among the hallmarks of brain aging is a decline in white matter volume and function which leads to an increase in neurological disorders,” Mikael Simons and Özgün Gökce, two of the researchers who carried out the study, told Medical Xpress. “White matter contains nerve fibers (axons), which are extensions of nerve cells (neurons). Many of these nerve fibers are surrounded by a type of sheath or covering called myelin, which allows our neurons to communicate fast, and gives white matter its color.”

Is a Gerontologist and Clinical Social Worker on a mission to rethink aging, longevity & mental health.

Ms. Anderson was also the former lead singer of the American Rock group, The Donnas (https://en.wikipedia.org/wiki/The_Donnas), where she was the lead vocalist for 20 years, performing throughout the U.S., as well as internationally, and had performances / appearances on major network shows including Saturday Night Live, David Letterman and Late Night with Conan O’Brien.

Continue reading “Brett Anderson, MSG, MSW — Journey From Rock Musician To Rethinking Aging, Longevity & Mental Health” »

On December 6–7, 2022, the Buck Institute for Research on Aging will be hosting the Longevity Summit 2022. Lifespan.io is pleased to announce that we are an official media partner for this upcoming conference.

The Summit will see many of the leading experts in the field coming together in the grounds of the architecturally distinct Buck Institute. It is being framed as a peer-to-peer learning experience aiming to unite longevity entrepreneurs, pharma and biotech companies, investors, researchers, and government organizations.

Here’s what the organizers had to say about the event:

Dr Brian Kennedy explains why verifying longevity interventions work is key and why the transition to human trials is so important.

Brian Kennedy is one of the busiest people in the longevity business, with fingers in many of the most interesting antiaging pies. He was at the Longevity Investors Conference recently, discussing some of the latest discoveries in longevity research and giving a longevity industry overview.

Continue reading “Dr Brian Kennedy — validating aging interventions and why rapamycin is the gold standard” »